A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis.
Colorectal Cancer With Liver Metastasis
DRUG: Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.
ORR, The objective response rate (ORR) in resectable pMMR/MSS colorectal cancer liver metastasis (CRLM) patients after neoadjuvant treatment with ivosimab combined with XELOX/FOLFOX., 4months
The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis